| The highly homologous T-Box transcription factors, TBX2 and TBX3, have distinct roles in the oncogenic process J Peres, E Davis, S Mowla, DC Bennett, JA Li, S Wansleben, S Prince Genes & cancer 1 (3), 272-282, 2010 | 104 | 2010 |
| T-box transcription factors in cancer biology S Wansleben, J Peres, S Hare, CR Goding, S Prince Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (2), 380-391, 2014 | 74 | 2014 |
| The T-box transcription factor, TBX3, is sufficient to promote melanoma formation and invasion J Peres, S Prince Molecular cancer 12, 1-5, 2013 | 70 | 2013 |
| The roles and regulation of TBX3 in development and disease SF Khan, V Damerell, R Omar, M Du Toit, M Khan, HM Maranyane, ... Gene 726, 144223, 2020 | 67 | 2020 |
| The T-box transcription factor TBX3 drives proliferation by direct repression of the p21WAF1 cyclin-dependent kinase inhibitor T Willmer, S Hare, J Peres, S Prince Cell division 11, 1-13, 2016 | 48 | 2016 |
| The T-Box transcription factor 3 in development and cancer T Willmer, A Cooper, J Peres, R Omar, S Prince Bioscience trends 11 (3), 254-266, 2017 | 44 | 2017 |
| The T-box transcription factor, TBX3, is a key substrate of AKT3 in melanomagenesis J Peres, S Mowla, S Prince Oncotarget 6 (3), 1821, 2015 | 44 | 2015 |
| The palladacycle, AJ-5, exhibits anti-tumour and anti-cancer stem cell activity in breast cancer cells S Aliwaini, J Peres, WL Kröger, A Blanckenberg, J de La Mare, AL Edkins, ... Cancer Letters 357 (1), 206-218, 2015 | 40 | 2015 |
| The T-Box factor TBX3 is important in S-phase and is regulated by c-Myc and cyclin A-CDK2 T Willmer, J Peres, S Mowla, A Abrahams, S Prince Cell Cycle 14 (19), 3173-3183, 2015 | 39 | 2015 |
| A novel role for the anti-senescence factor TBX2 in DNA repair and cisplatin resistance S Wansleben, E Davis, J Peres, S Prince Cell death & disease 4 (10), e846-e846, 2013 | 38 | 2013 |
| The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the TBX3 transcription factor J Peres, EM Kwesi-Maliepaard, F Rambow, L Larue, S Prince Cancer letters 405, 111-119, 2017 | 34 | 2017 |
| Doxorubicin resistance in breast cancer: a novel role for the human protein AHNAK T Davis, G van Niekerk, J Peres, S Prince, B Loos, AM Engelbrecht Biochemical pharmacology 148, 174-183, 2018 | 29 | 2018 |
| Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo R Jivan, J Peres, LH Damelin, R Wadee, RB Veale, S Prince, ... Cancer letters 417, 1-10, 2018 | 27 | 2018 |
| Metformin‐induced alterations in nucleotide metabolism cause 5‐fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma C Mynhardt, LH Damelin, R Jivan, J Peres, S Prince, RB Veale, ... Journal of cellular biochemistry 119 (1), 1193-1203, 2018 | 19 | 2018 |
| Targeting the oncogenic TBX2 transcription factor with chromomycins BDB Sahm, J Peres, P Rezende-Teixeira, EA Santos, PC Branco, ... Frontiers in chemistry 8, 110, 2020 | 13 | 2020 |
| The c-Myc/AKT1/TBX3 axis is important to target in the treatment of embryonal rhabdomyosarcoma D Sims, HM Maranyane, V Damerell, D Govender, AW Isaacs, J Peres, ... Cancers 12 (2), 501, 2020 | 11 | 2020 |
| TBX3 promotes melanoma migration by transcriptional activation of ID1, which prevents activation of E-cadherin by MITF J Peres, V Damerell, J Chauhan, A Popovic, PY Desprez, MD Galibert, ... Journal of Investigative Dermatology 141 (9), 2250-2260. e2, 2021 | 8 | 2021 |
| Cytoskeletal tubulin competes with actin to increase deformability of metastatic melanoma cells G Higgins, J Peres, T Abdalrahman, MH Zaman, DM Lang, S Prince, ... Experimental Cell Research 394 (2), 112154, 2020 | 4 | 2020 |
| Tendon‐like tether formation for tongue‐base advancement in an ovine model using a novel implant device intended for the surgical management of obstructive sleep apnoea R Hendricks, E Hofmann, J Peres, S Prince, J Hille, NH Davies, ... Journal of Biomedical Materials Research Part B: Applied Biomaterials 109 (7 …, 2021 | 1 | 2021 |
| Abstract B19: The oncogenic TBX2 activates the ATM-CHK2-p53 axis to confer cisplatin resistance in breast cancer and melanoma S Kimani, S Wansbelen, E Davis, J Peres, S Prince Molecular Cancer Research 14 (11_Supplement), B19-B19, 2016 | 1 | 2016 |
